<DOC>
	<DOCNO>NCT01010516</DOCNO>
	<brief_summary>Statin therapy fully eliminate cardiovascular disease ( CVD ) risk associate low high density lipoprotein-C ( HDL-C ) high triglyceride level . It currently unknown would best treatment option patient mixed hyperlipidemia fail meet lipid target statin monotherapy conventional , i.e . high dose rosuvastatin conventional statin dose plus micronized fenofibrate conventional statin dose plus niacin/laropiprant . The aim present study compare efficacy high-dose rosuvastatin vs conventional statin dose plus micronized fenofibrate vs conventional statin dose plus extended-release niacin/laropiprant lipid profile patient mixed hyperlipidemia . The primary efficacy endpoint change non-HDL-C level 6 month treatment initiation .</brief_summary>
	<brief_title>Comparison High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin Treatment Mixed Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>NonHDLC target goal accord NCEPATP III 3 month treatment conventional statin dos , e.g . simvastatin 1040 mg , atorvastatin 1040 mg rosuvastatin 520 mg Known CVD , triglycerides &gt; 500 mg/dL , renal disease ( serum creatinine level &gt; 1.6 mg/dL ) , hypothyroidism [ thyroid stimulate hormone ( TSH ) &gt; 5 IU/mL ] , liver disease ( ALT and/or AST level &gt; 3fold upper limit normal 2 consecutive measurement ) , alcohol consumption &gt; 3 drinks/day men &gt; 2 drinks/day woman , current previous gout . Patients diabetes include study adequately control ( HbA1c &lt; 7 % ) one 2 antidiabetic drug ( change treatment make study period ) . Patients hypertension include study stable medication least 3 month blood pressure adequately control ( change treatment make study period ) . Patients currently take lipidlowering drug ( statin conventional dose ) stop less 4 week study entry exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>